The finding that mutations in the Gaucher's Disease (GD) gene GBA1 are a strong risk factor for Parkinson's Disease (PD) has allowed for unique insights into pathophysiology centered on disruption of the autophagiclysosomal pathway. Protein aggregations in the form of Lewy bodies and the effects of canonical PD mutations that converge on the lysosomal degradation system suggest that neurodegeneration in PD is mediated by dysregulation of protein homeostasis. The well-characterized clinical and pathological relationship between PD and the lysosomal storage disorder GD emphasizes the importance of dysregulated protein metabolism in neurodegeneration, and one intriguing piece of this relationship is a shared phenotype of autophagic-lysosomal dysfunction in both diseases. Translational application of these findings may be accelerated by the use of midbrain dopamine neuronal models derived from induced pluripotent stem cells (iPSCs) that recapitulate several pathological features of GD and PD. In this review, we discuss evidence linking autophagic dysfunction to the pathophysiology of GD and GBA1-linked parkinsonism and focus more specifically on studies performed recently in iPSC-derived neurons.
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Gaucher's Disease: Clinical description and pathophysiology
GD is an autosomal recessive lysosomal storage disorder and is caused by mutations in GBA1, a gene encoding the lysosomal hydrolase β-glucocerebrosidase (GCase) (Sidransky, 2012) . GCase hydrolyzes glucosylceramide (GluCer) to ceramide and glucose, and its deficiency causes GluCer to accumulate within lysosomes (Beutler, 1992; Murray and Jin, 1995; Willemsen et al., 1988) . Peripheral accumulation of GluCer chronically activates inflammatory pathways as GluCer cannot be digested by mutant macrophages, ultimately leading to variable symptoms of hematopoietic imbalance such as hepatosplenomegaly, pancytopenia, and bone abnormalities (Dandana et al., 2016; Pandey et al., 2017) . These features reflect the classical presentation of GD, but variants have been further classified according to disease severity, ageat-onset, and involvement of the nervous system. Adult-onset nonneuronopathic GD is the most common presentation and is classified as Type I. Types II and III are characterized by severe early childhood neurodegeneration and later onset ataxia with myoclonic seizures, respectively (Westbroek et al., 2011) . GluCer accumulates in affected tissues in each type of GD, but cellular and environmental factors affecting phenotypic variation are not yet fully understood. While specific mutations do not predict many phenotypic features, they have been correlated broadly with GD classification. For example, the most common mutation, N370S, has been associated with Type I GD, while the severely destabilizing L444P mutation is strongly associated with the development of Types II and III. This association could be due to the severity of each mutation related to protein destabilizing effects or catalytic deficiency, where more damaging variants are associated with the early pediatric onset and severe neurodegeneration (Sidransky, 2012) . While there are over 300 distinct GBA1 mutations known, they all result in loss of enzymatic function and protein through either premature stop codons or premature degradation through cellular quality control mechanisms (Grabowski, 2008) .
Lysosomal proteins including GCase are synthesized in the endoplasmic reticulum (ER). For proper folding to occur, the nascent peptide must be modified by N-glycosylation which aids in the recognition by molecular chaperones including heat shock protein (Hsp) homologues, ER lectins such as calnexin, and thiol oxidoreductases (Bendikov-Bar and Horowitz, 2012) . If the protein is not correctly folded, it is re-glycosylated to be folded by chaperones again, and mutated GCase is misfolded and retained in the ER by these quality control mechanisms. Following repeated cycles of glycosylation and attempted folding by chaperones, the protein is exported from the ER and finally degraded by the ubiquitin-proteasome pathway rather than
